This individual patient data review concluded that combination therapy with dipyridamole plus aspirin reduced vascular death/stroke and other vascular events when compared with aspirin alone in patients after a transient ischaemic attack or stroke. There is some uncertainty regarding this conclusion given potential biases and assumptions within the review.
Searching
The search updated that of a previous review in which MEDLINE (1966 MEDLINE ( to 2001 , EMBASE (1980 EMBASE ( to 2002 , the Cochrane Library (2002, Issue 4) , and the Web of Science (1981 Science ( to 2002 were searched; details of the new search were not provided. References from relevant articles and reviews were scanned. Trialists and the manufacturer of dipyridamole were contacted. No language restrictions were applied. Both published and unpublished trials were eligible.
Study selection
Randomised controlled trials (RCTs) that compared dipyridamole plus aspirin with aspirin alone were eligible for inclusion. Individuals with a previous history of ischaemic cerebrovascular disease or transient ischaemic attack were eligible for inclusion.
The primary outcome was a composite outcome of death from any vascular cause, non-fatal stroke and non-fatal myocardial infarction. The secondary outcomes included vascular death or non-fatal stroke, all death, vascular death, fatal and non-fatal stroke, and fatal and non-fatal myocardial infarction.
Pre-specified subgroup analyses for the primary outcome were: age (up to 65 years versus 65 years and over), gender, qualifying event (transient ischaemic attack versus stroke), type of vessel disease (small versus large), dose of aspirin (less than 75mg versus 75mg or more), formulation of dipyridamole (immediate versus extended release), time between event and randomisation (less than one week versus one week to one month versus one to six months) and history of hypertension, stroke, diabetes, or ischaemic heart disease. Subgroup analyses were also performed according to baseline risk with risk derived from two models based on different risk factors
The included trials used conventional-release or modified-release dipyridamole (daily dose 150mg to 400 mg) plus aspirin (daily dose ranged from 50mg to 990mg). The average age of included patients was 65 years; almost two-thirds were male.
Two reviewers selected trials for inclusion. It was unclear whether this was completed independently or how disagreements were resolved.
